Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immunodeficiencies and Inherited Disorders in Children.

Neven B, Diana JS, Castelle M, Magnani A, Rosain J, Touzot F, Moreira B, Fremond ML, Briand C, Bendavid M, Levy R, Morelle G, Vincent M, Magrin E, Bourget P, Chatenoud L, Picard C, Fischer A, Moshous D, Blanche S.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1363-1373. doi: 10.1016/j.bbmt.2019.03.009. Epub 2019 Mar 12.

PMID:
30876929
2.

Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.

Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil JA, Hongeng S, Magrin E, Schiller GJ, Payen E, Semeraro M, Moshous D, Lefrere F, Puy H, Bourget P, Magnani A, Caccavelli L, Diana JS, Suarez F, Monpoux F, Brousse V, Poirot C, Brouzes C, Meritet JF, Pondarré C, Beuzard Y, Chrétien S, Lefebvre T, Teachey DT, Anurathapan U, Ho PJ, von Kalle C, Kletzel M, Vichinsky E, Soni S, Veres G, Negre O, Ross RW, Davidson D, Petrusich A, Sandler L, Asmal M, Hermine O, De Montalembert M, Hacein-Bey-Abina S, Blanche S, Leboulch P, Cavazzana M.

N Engl J Med. 2018 Apr 19;378(16):1479-1493. doi: 10.1056/NEJMoa1705342.

3.

Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial.

Tardieu M, Zérah M, Gougeon ML, Ausseil J, de Bournonville S, Husson B, Zafeiriou D, Parenti G, Bourget P, Poirier B, Furlan V, Artaud C, Baugnon T, Roujeau T, Crystal RG, Meyer C, Deiva K, Heard JM.

Lancet Neurol. 2017 Sep;16(9):712-720. doi: 10.1016/S1474-4422(17)30169-2. Epub 2017 Jul 14.

PMID:
28713035
4.

Gene Therapy in a Patient with Sickle Cell Disease.

Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, Caccavelli L, Neven B, Bourget P, El Nemer W, Bartolucci P, Weber L, Puy H, Meritet JF, Grevent D, Beuzard Y, Chrétien S, Lefebvre T, Ross RW, Negre O, Veres G, Sandler L, Soni S, de Montalembert M, Blanche S, Leboulch P, Cavazzana M.

N Engl J Med. 2017 Mar 2;376(9):848-855. doi: 10.1056/NEJMoa1609677.

5.

Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas.

Neuzillet C, Rousseau B, Kocher H, Bourget P, Tournigand C.

Pharmacol Ther. 2017 Jun;174:145-172. doi: 10.1016/j.pharmthera.2017.02.028. Epub 2017 Feb 14. Review.

PMID:
28223233
6.

Midostaurin in Advanced Systemic Mastocytosis.

Chandesris MO, Damaj G, Canioni D, Brouzes C, Lhermitte L, Hanssens K, Frenzel L, Cherquaoui Z, Durieu I, Durupt S, Gyan E, Beyne-Rauzy O, Launay D, Faure C, Hamidou M, Besnard S, Diouf M, Schiffmann A, Niault M, Jeandel PY, Ranta D, Gressin R, Chantepie S, Barete S, Dubreuil P, Bourget P, Lortholary O, Hermine O; CEREMAST Study Group.

N Engl J Med. 2016 Jun 30;374(26):2605-7. doi: 10.1056/NEJMc1515403. No abstract available.

PMID:
27355555
7.

Plasma and intraprostatic concentrations of ertapenem following preoperative single dose administration: a single-centre prospective experience and clinical implications-the ERTAPRO study.

Dariane C, Amin A, Lortholary O, Lalli A, Michel C, Le Guilchet T, Treluyer JM, Nguyen-Khoa T, De Toma C, Urien S, Méjean A, Bourget P, Timsit MO.

Int J Antimicrob Agents. 2016 Aug;48(2):168-74. doi: 10.1016/j.ijantimicag.2016.04.027. Epub 2016 Jun 2.

PMID:
27324263
8.

Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.

Negre O, Eggimann AV, Beuzard Y, Ribeil JA, Bourget P, Borwornpinyo S, Hongeng S, Hacein-Bey S, Cavazzana M, Leboulch P, Payen E.

Hum Gene Ther. 2016 Feb;27(2):148-65. doi: 10.1089/hum.2016.007.

9.

Concentrations plasmatiques et intra-prostatiques d'ertapénème après administration préopératoire : expérience prospective monocentrique - étude ERTAPRO.

Dariane C, Amin A, Lortholary O, Lalli A, Michel C, Le Guilchet T, Treluyer J, Nguyen-Khoa T, De Toma C, Urien S, Méjean A, Bourget P, Timsit M.

Prog Urol. 2015 Nov;25(13):775. doi: 10.1016/j.purol.2015.08.121. French. No abstract available.

PMID:
26544316
10.

State of the art and future directions of pancreatic ductal adenocarcinoma therapy.

Neuzillet C, Tijeras-Raballand A, Bourget P, Cros J, Couvelard A, Sauvanet A, Vullierme MP, Tournigand C, Hammel P.

Pharmacol Ther. 2015 Nov;155:80-104. doi: 10.1016/j.pharmthera.2015.08.006. Epub 2015 Aug 20. Review.

PMID:
26299994
11.

Physicochemical and microbiological stability of azathioprine in InOrpha suspending agent studied under various conditions.

Amin A, Bourget P, Vidal F, Cartier F, Beauvais R, Afonso Vdo N.

Int J Pharm Compd. 2015 Jan-Feb;19(1):73-7.

PMID:
25902631
12.

Physicochemical and microbiological stabilities of hydrocortisone in InOrpha suspending agent studied under various conditions.

Bourget P, Amin A, Vidal F, Pieyre M, El Dosso O, Beauvais R, Loeuillet R.

Int J Pharm Compd. 2014 Sep-Oct;18(5):427-31.

PMID:
25577893
13.

Routine application of Raman spectroscopy in the quality control of hospital compounded ganciclovir.

Amin A, Bourget P, Vidal F, Ader F.

Int J Pharm. 2014 Oct 20;474(1-2):193-201. doi: 10.1016/j.ijpharm.2014.08.028. Epub 2014 Aug 20.

PMID:
25148728
14.

[Raman spectroscopy applied to analytical quality control of injectable drugs: analytical evaluation and comparative economic versus HPLC and UV / visible-FTIR].

Bourget P, Amin A, Vidal F, Merlette C, Troude P, Corriol O.

J Pharm Belg. 2013 Sep;(3):32-45. French.

PMID:
24804411
15.

The contribution of Raman spectroscopy to the analytical quality control of cytotoxic drugs in a hospital environment: eliminating the exposure risks for staff members and their work environment.

Bourget P, Amin A, Vidal F, Merlette C, Troude P, Baillet-Guffroy A.

Int J Pharm. 2014 Aug 15;470(1-2):70-6. doi: 10.1016/j.ijpharm.2014.04.064. Epub 2014 May 2.

PMID:
24792972
16.

How to minimize toxic exposure to pyridine during continuous infusion of ceftazidime in patients with cystic fibrosis?

Bourget P, Amin A, Dupont C, Abely M, Desmazes-Dufeu N, Dubus JC, Jouani BL, Merlette C, Nové-Josserand R, Pages J, Panzo R, Vidal F, Voge F, Hubert D.

Antimicrob Agents Chemother. 2014 May;58(5):2849-55. doi: 10.1128/AAC.02637-13. Epub 2014 Mar 10.

17.

Comparison of Raman spectroscopy vs. high performance liquid chromatography for quality control of complex therapeutic objects: model of elastomeric portable pumps filled with a fluorouracil solution.

Bourget P, Amin A, Vidal F, Merlette C, Lagarce F.

J Pharm Biomed Anal. 2014 Mar;91:176-84. doi: 10.1016/j.jpba.2013.12.030. Epub 2014 Jan 3.

PMID:
24463044
18.

Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.

Bourget P, Amin A, Chandesris MO, Vidal F, Merlette C, Hirsch I, Cabaret L, Carvalhosa A, Mogenet A, Frenzel L, Damaj G, Lortholary O, Hermine O.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jan 1;944:175-81. doi: 10.1016/j.jchromb.2013.11.003. Epub 2013 Nov 15.

PMID:
24316764
19.

[Antibiotic treatment of appendicular peritonitis in children: is the oral route done?].

Berthe-Aucejo A, Postaire M, Cheikhlard A, Zahar JR, Bourget P.

Arch Pediatr. 2012 Dec;19(12):1303-7. doi: 10.1016/j.arcped.2012.09.015. Epub 2012 Oct 26. French.

PMID:
23107091
20.

[The Raman Spectroscopy (RS): A new tool for the analytical quality control of injectable in health settings. Comparison of RS technique versus HPLC and UV/Vis-FTIR, applied to anthracyclines as anticancer drugs].

Bourget P, Amin A, Moriceau A, Cassard B, Vidal F, Clement R.

Pathol Biol (Paris). 2012 Dec;60(6):369-79. doi: 10.1016/j.patbio.2011.10.010. Epub 2012 Oct 9. French.

PMID:
23062768
21.

[A medical-pharmaceutical partnership model as a contributor to the success in conditioning regimen for allogenic hematopoietic stem cell transplantation in adults: a cross-reflection on our organizations].

Bourget P, Falaschi L, Suarez F, Galland V, Blot D, Trompette C, Sibon D, Fontbrune FS, Merlette C, Vidal F, Corriol O, Giraud B, Broissand C, Clement R, Hermine O.

Bull Cancer. 2012 Jun;99(6):643-53. doi: 10.1684/bdc.2012.1589. French.

22.

[Evaluation of circadian variation of blood pressure by ambulatory blood pressure monitoring in an elderly diabetic population with or without orthostatic hypotension].

Lanthier L, Touchette M, Bourget P, St-Georges C, Walker C, Tessier DM.

Geriatr Psychol Neuropsychiatr Vieil. 2011 Mar;9(1):59-66. doi: 10.1684/pnv.2011.0257. French.

PMID:
21586378
23.

Safety and quality assurance of chemotherapeutic preparations in a hospital production unit: acceptance sampling plan and economic impact.

Paci A, Borget I, Mercier L, Azar Y, Desmaris RP, Bourget P.

J Oncol Pharm Pract. 2012 Jun;18(2):163-70. doi: 10.1177/1078155211402865. Epub 2011 May 10.

PMID:
21558471
24.

Mechanical performances of elastomers used in diffusers.

Guiffant G, Durussel JJ, Flaud P, Vigier JP, Dupont C, Bourget P, Merckx J.

Med Devices (Auckl). 2011;4:71-6. doi: 10.2147/MDER.S18633. Epub 2011 Jun 14.

25.

Microbiological and physicochemical stability of oxycodone hydrochloride solutions for patient-controlled delivery systems.

Amri A, Ben Achour A, Chachaty E, Mercier L, Bourget P, Paci A.

J Pain Symptom Manage. 2010 Jul;40(1):87-94. doi: 10.1016/j.jpainsymman.2009.11.323. Epub 2010 Jun 8.

PMID:
20570483
26.

New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity.

Storme T, Deroussent A, Mercier L, Prost E, Re M, Munier F, Martens T, Bourget P, Vassal G, Royer J, Paci A.

J Pharmacol Exp Ther. 2009 Feb;328(2):598-609. doi: 10.1124/jpet.108.144170. Epub 2008 Nov 18.

PMID:
19017849
27.

Microbiological and physicochemical stability of fentanyl and sufentanil solutions for patient-controlled delivery systems.

Chapalain-Pargade S, Laville I, Paci A, Chachaty E, Mercier L, Bourget P.

J Pain Symptom Manage. 2006 Jul;32(1):90-7.

PMID:
16824989
28.

Application of an acceptance sampling plan for post-production quality control of chemotherapeutic batches in an hospital pharmacy.

Borget I, Laville I, Paci A, Michiels S, Mercier L, Desmaris RP, Bourget P.

Eur J Pharm Biopharm. 2006 Aug;64(1):92-8. Epub 2006 Jun 5.

PMID:
16750352
29.

Evaluation of the pharmacokinetic profile and analgesic efficacy of oral morphine after total hip arthroplasty.

Manoir BD, Bourget P, Langlois M, Szekely B, Fischler M, Chauvin M, Paci A, Fletcher D.

Eur J Anaesthesiol. 2006 Sep;23(9):748-54. Epub 2006 May 24.

PMID:
16723055
30.

Near infrared spectroscopy and process analytical technology to master the process of busulfan paediatric capsules in a university hospital.

Paris I, Janoly-Dumenil A, Paci A, Mercier L, Bourget P, Brion F, Chaminade P, Rieutord A.

J Pharm Biomed Anal. 2006 Jun 16;41(4):1171-8. Epub 2006 Apr 18.

PMID:
16621419
31.

Microbial growth tests in anti-neoplastic injectable solutions.

Paris I, Paci A, Rey JB, Bourget P.

J Oncol Pharm Pract. 2005 Mar;11(1):7-12.

PMID:
16460598
32.

In vitro echogenicity characterization of poly[lactide-coglycolide] (plga) microparticles and preliminary in vivo ultrasound enhancement study for ultrasound contrast agent application.

Lavisse S, Paci A, Rouffiac V, Adotevi C, Opolon P, Peronneau P, Bourget P, Roche A, Perricaudet M, Fattal E, Lassau N.

Invest Radiol. 2005 Aug;40(8):536-44.

PMID:
16024992
34.

Quality control and stability study using HPTLC: applications to cyclophosphamide in various pharmaceutical products.

Bouligand J, Storme T, Laville I, Mercier L, Oberlin O, Vassal G, Bourget P, Paci A.

J Pharm Biomed Anal. 2005 Jun 1;38(1):180-5.

PMID:
15907638
35.

Liquid chromatography-mass spectrometry assay for quantitation of ifosfamide and its N-deschloroethylated metabolites in rat microsomal medium.

Storme T, Mercier L, Deroussent A, Re M, Martens T, Royer J, Bourget P, Vassal G, Paci A.

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jun 25;820(2):251-9. Epub 2005 Apr 25.

PMID:
15899378
36.

[Shelf-lives of morphine and pethidine solutions stored in patient-controlled analgesia devices: physico-chemical and microbiological stability study].

Laville I, Mercier L, Chachaty E, Bourget P, Paci A.

Pathol Biol (Paris). 2005 May;53(4):210-6. French.

PMID:
15850954
37.

Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance.

Elias D, Matsuhisa T, Sideris L, Liberale G, Drouard-Troalen L, Raynard B, Pocard M, Puizillou JM, Billard V, Bourget P, Ducreux M.

Ann Oncol. 2004 Oct;15(10):1558-65.

PMID:
15367418
38.
39.

Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients.

Launay-Vacher V, Izzedine H, Rey JB, Rixe O, Chapalain S, Nourdine S, Paci A, Bourget P, Deray G.

Med Sci Monit. 2004 May;10(5):CR209-12. Epub 2004 Apr 28.

PMID:
15114271
40.
41.
42.

Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis.

Elias D, El Otmany A, Bonnay M, Paci A, Ducreux M, Antoun S, Lasser P, Laurent S, Bourget P.

Oncology. 2002;63(4):346-52.

PMID:
12417789
43.

[Pharmaceutical traceability integrated with the patient file. Development of a computerized hospital application].

Bourget P, Barath V, Guntz JP, Bourgain JL, Demirdjian S, Rongeat S.

Pathol Biol (Paris). 2001 Oct;49(8):624-33. French.

PMID:
11692750
44.

Application of high-performance, thin-layer chromatography to quality control of antimetabolite analogue infusion bags.

Perello L, Demirdjian S, Dory A, Bourget P.

J AOAC Int. 2001 Jul-Aug;84(4):1296-300.

PMID:
11501935
45.

[Role and functional spectrum of HPTLC in a hospital pharmaceutical quality control program].

Bourget P, Perello L, Demirdjian S.

Pathol Biol (Paris). 2001 Feb;49(1):86-95. Review. French.

PMID:
11265228
46.

[Safe oral administration of etoposide: application to pediatric practice].

Legros MH, Bourget P, Rongeat S, Osmond S, Pein F, Hartmann O.

Therapie. 1999 Jul Aug;54(4):487-9. French. No abstract available.

PMID:
10667116
47.

[Making the administration of dry oral forms of cytotoxic medications safer].

Legros MH, Bourget P, Demirdjian S, Osmond S, Hartmann O.

Therapie. 1999 Jul Aug;54(4):485-7. French. No abstract available.

PMID:
10667115
48.

Clinical pharmacokinetics of ciprofloxacin in patients with major burns.

Lesne-Hulin A, Bourget P, Ravat F, Goudin C, Latarjet J.

Eur J Clin Pharmacol. 1999 Sep;55(7):515-9.

PMID:
10501821
49.

[Pharmacokinetics of fusidic acid in patients with seriously infected burns].

Lesne-Hulin A, Bourget P, Le Bever H, Carsin H.

Pathol Biol (Paris). 1999 May;47(5):486-90. French.

PMID:
10418024
50.

Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics?

Courteix C, Bourget P, Caussade F, Bardin M, Coudore F, Fialip J, Eschalier A.

J Pharmacol Exp Ther. 1998 Apr;285(1):63-70.

PMID:
9535995

Supplemental Content

Loading ...
Support Center